- PA5-30641 - Invitrogen Antibodies ZNF207 antibody

Submitted references System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.

Wang X, Zhou T, Chen X, Wang Y, Ding Y, Tu H, Gao S, Wang H, Tang X, Yang Y
Journal for immunotherapy of cancer 2022 Mar;10(3)

A distinct isoform of ZNF207 controls self-renewal and pluripotency of human embryonic stem cells.

Fang F, Xia N, Angulo B, Carey J, Cady Z, Durruthy-Durruthy J, Bennett T, Sebastiano V, Reijo Pera RA
Nature communications 2018 Oct 22;9(1):4384

BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment.

Toledo CM, Herman JA, Olsen JB, Ding Y, Corrin P, Girard EJ, Olson JM, Emili A, DeLuca JG, Paddison PJ
Developmental cell 2014 Feb 10;28(3):282-94

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using ZNF207 Polyclonal Antibody (Product # PA5-30641). Sample (30 µg of whole cell lysate). Lane A: A549. 10% SDS PAGE. ZNF207 Polyclonal Antibody (Product # PA5-30641) diluted at 1:1,000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of ZNF207 in paraformaldehyde-fixed HeLa cells using a ZNF207 polyclonal antibody (Product # PA5-30641) at a 1:500 dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using ZNF207 (Product # PA5-30641) antibody at 1:250 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 ZNF207 co-localizes with master transcription factors in hESCs to regulate pluripotency and neuronal gene expression. a Enriched motifs from de novo motif search of sequences under ZNF207 peaks. Note the identification of consensus OCT4/SOX2 binding but also other known transcription factor binding motifs. Statistical significance (E-values) is indicated below the motif logo. b Heatmap depicts ZNF207, OCT4 (GSM1124067), and SOX2 (GSM1701825) ChIP-Seq signals at TSSs. c Protein interactions between ZNF207 with OCT4 and SOX2. Co-IP using cell extracts from hESCs was performed using anti-OCT4 and anti-SOX2 antibody. Western blotting was carried out with anti-ZNF207 antibody. Control IP was performed using anti-IgG antibody. Reverse co-IP was performed using anti-ZNF207 antibody, and western blotting was then performed with anti-OCT4 or anti-SOX2 antibody. Input was shown as loading control. d Venn diagrams show overlaps of genes bound by OCT4, SOX2, and ZNF207 in hESCs. e Gene ontology analysis of genes that are directed regulated by ZNF207. Blue bars represent the number of genes and orange bars represent p -value. p -value is calculated using hypergeometric distribution. f ChIP-Seq tracks show co-localization of ZNF207, SOX2, and OCT4 at the regulatory sequences of pluripotency genes. The scale bars indicate the size of the chromosome. The light pink boxes highlight the co-bound regions. g ChIP-Seq tracks show co-localization of ZNF207, SOX2, and OCT4 at

PA5-30641

Antibody data